Summary: Evaluated low-dose rosuvastatin 10 mg versus placebo in patients with heart failure (EF < 40%) and New York Heart Association functional class II-IV symptoms without an indication for cholesterol lowering therapy.

The primary endpoint of composite cardiovascular death, nonfatal MI or nonfatal stroke was not met. Hospitalizations were reduced.

Original Publication:

N Engl J Med. 2007 Nov 29;357(22):2248-61. Epub 2007 Nov 5.

Eponym: COntrolled ROsuvastatin multiNAtional study